This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1t7j

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1t7j.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1t7j.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1t7j| PDB=1t7j | SCENE= }}
{{STRUCTURE_1t7j| PDB=1t7j | SCENE= }}
-
'''crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 protease (L63P/V82T/I84V)'''
+
===crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 protease (L63P/V82T/I84V)===
-
==Overview==
+
<!--
-
The screening of known HIV-1 protease inhibitors against a panel of multi-drug-resistant viruses revealed the potent activity of TMC126 on drug-resistant mutants. In comparison to amprenavir, the improved affinity of TMC126 is largely the result of one extra hydrogen bond to the backbone of the protein in the P2 pocket. Modification of the substitution pattern on the phenylsulfonamide P2' substituent of TMC126 created an interesting SAR, with the close analogue TMC114 being found to have a similar antiviral activity against the mutant and the wild-type viruses. X-ray and thermodynamic studies on both wild-type and mutant enzymes showed an extremely high enthalpy driven affinity of TMC114 for HIV-1 protease. In vitro selection of mutants resistant to TMC114 starting from wild-type virus proved to be extremely difficult; this was not the case for other close analogues. Therefore, the extra H-bond to the backbone in the P2 pocket cannot be the only explanation for the interesting antiviral profile of TMC114. Absorption studies in animals indicated that TMC114 has pharmacokinetic properties comparable to currently approved HIV-1 protease inhibitors.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15771427}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15771427 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15771427}}
==About this Structure==
==About this Structure==
Line 33: Line 37:
[[Category: Substrate envelope]]
[[Category: Substrate envelope]]
[[Category: Thermodynamic]]
[[Category: Thermodynamic]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 09:38:02 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 20:32:13 2008''

Revision as of 17:32, 28 July 2008

Image:1t7j.png

Template:STRUCTURE 1t7j

crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 protease (L63P/V82T/I84V)

Template:ABSTRACT PUBMED 15771427

About this Structure

1T7J is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor., Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB, J Med Chem. 2005 Mar 24;48(6):1813-22. PMID:15771427

Page seeded by OCA on Mon Jul 28 20:32:13 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1t7j"
Personal tools